Results 71 to 80 of about 68,946 (284)

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

Advanced Science, EarlyView.
Relapsed and refractory multiple myeloma remains a major clinical challenge. This study shows that FOXM1 contributes to resistance against BH3 mimetics in multiple myeloma cells. The FOXM1 inhibitor NB73 enhances the effectiveness of BH3 mimetics by reducing FOXM1 expression and suppressing the MYC pathway.
Zhi Wen, Yidan Wang, Kathryn C. Fox, Adam M. Bissonnette, Luke F. Moat, Terrie E. Kitchner, Kelsey Springstroh, Sung Hoon Kim, Dagna S. Sheerar, Patcharon Tanawattanacharoen, Chady A. Leon, Seth O. Fagbemi, John A. Katzenellenbogen, Scott J. Hebbring, Benita S. Katzenellenbogen, Siegfried Janz, Adedayo A. Onitilo   +16 more
wiley   +1 more source

Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias

The Oncologist, 2002
Abstract Learning Objectives After taking all of the CME courses in this supplement the reader will be able to: Describe the basic biology of various leukemias, multiple myeloma, and myelodysplastic syndrome (MDS).
openaire   +3 more sources

Targeting the oligomerization of BCR/ABL by membrane permeable competitive peptides inhibits the proliferation of Philadelphia Chromosome positive leukemic cells [PDF]

, 2013
The BCR/ABL fusion protein is the hallmark of Philadelphia Chromosome positive (Ph+) leukemia. The constitutive activation of the ABL-kinase in BCR/ABL cells induces the leukemic phenotype.
Beißert, Tim, Goldblum, Amiram, Mahajna, Jamal, Mian, Afsar Ali, Najajreh, Yousef, Oancea, Claudia, Ottmann, Oliver Gerhard, Ruthardt, Martin, Schüll, Marion   +8 more
core  

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia

PLoS ONE, 2014
Resistance to imatinib (Gleevec®) in cancer cells is frequently because of acquired point mutations in the kinase domain of BCR-ABL. Ponatinib, also known as AP24534, is an oral multi-targeted tyrosine kinase inhibitor (TKI), and it has been investigated
S. Okabe, T. Tauchi, S. Kimura, T. Maekawa, T. Kitahara, Yoko Tanaka, K. Ohyashiki   +6 more
semanticscholar   +1 more source

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

Exploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu, Guiyu Dai, Yanyan Chen, Lihua Tan, Hanqing Liu, Meiwan Chen   +5 more
wiley   +1 more source

CRISPR/CAS9-mediated knockout of Abi1 inhibits p185Bcr-Abl-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways

Journal of Hematology & Oncology, 2020
Background Abl interactor 1 (Abi1) is a downstream target of Abl tyrosine kinases and a component of the WAVE regulatory complex (WRC) that plays an important role in regulating actin cytoskeleton remodeling and membrane receptor signaling. While studies
James Faulkner, Peixin Jiang, Delaney Farris, Ryan Walker, Zonghan Dai   +4 more
doaj   +1 more source

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source